Community news|31/01/22

The CJEU confirms the identification of BPA as an endocrine disruptor for health

Home > The news of EUROGIP and occupational risks in Europe > The CJEU confirms the identification of BPA as an endocrine disruptor for health

The Court of Justice of the European Union (CJEU) has confirmed on appeal the identification of bisphenol A (BPA) as a substance of very high concern(1) for its endocrine disrupting properties for human health.

It has indeed rejected the appeal of the European Plastics Manufacturers’ Association, PlasticsEurope against the judgment of the General Court of the European Union of 20 September 2019, PlasticsEurope/ECHA (T-636/17) in a judgment of 21 December 2021. The European Chemicals Agency (ECHA) had included BPA on the list of candidate substances for authorisation due to its endocrine disrupting properties and potential serious health effects, which the judgment confirms.

As a reminder, PlasticsEurope brought three cases before the European Court of Justice concerning the three hazardous properties of bisphenol A: reproductive toxicity (case T-185/17), endocrine disruptor for human health (case C-876/19 P), and endocrine disruptor for the environment. The first two cases have now been closed with the appeal confirming the correctness of the ECHA decisions. The third is still pending.

(1) Substance of Very High Concern (SVHC) as defined in Regulation 1907/2006 (REACH)

Judgment of the Court of Justice

Discover other news



ITALY: provisional assessment of work-related accidents in 2022

According to the provisional data it has just published, INAIL observes between January and December 2022 a 25.7% increase in the number of accident reports (697,773). The number of fatal accidents is decreasing, despite an increase in commuting fatalities, compared to 2021.